Hovione New Jersey

Manufacturing Plant and R&D Center

The site houses a high-caliber team of professionals with broad experience in developing and commercializing products across Drug Substance, Particle Engineering, and Continuous Drug Product processes.

The Hovione New Jersey site commenced operations in 2002 providing process development and small volume API manufacturing. Since then its technologies portfolio has greatly expanded with additional offerings in highly potent compounds, a variety of particle engineering capabilities and drug product continuous tableting services. The site was first inspected by the FDA in 2007 and hence has had an excellent track record with multiple regulatory authorities around the globe.

The Hovione New Jersey site is again expanding its capacity in the U.S. with the addition of a size 2 spray dryer at our existing facility at 40 Lake Drive, ready for commercial launch in late 2024. 

The New Jersey campus has welcomed a new facility located at 89 Twin Rivers Drive. This is an adjacent building which will carry the same FDA registration number and contain two state of the art size 3 pharmaceutical spray dryers. Commercial operation of these new spray dryers is planned for late 2025 and mid 2026 respectively. Our continued growth will leverage the latest technologies to best serve our customers and patients with an integrated offering from Drug Substance to Drug Product at Hovione in New Jersey.

 

new jersey site exterior view of main entrance

Areas of Focused Expertise

The site boasts strong capabilities and physical assets in the following areas:

For details about production equipment – click here

 

Operations

  • Hovione New Jersey plant operates 24 hours a day 5 days a week.
  • Quality Control labs support production 24 hours a day 5 days a week.

 

Certifications

The site was rewarded with VPP Star Award by the Occupational Safety and Health Administration (OSHA) in 2007 and has successfully maintained this status since.

Hovione New Jersey is certified for the Customs-Trade Partnership Against Terrorism (C-TPAT) by the U.S. Customs and Border Protection (CBP).

 

For inquiries about Hovione New Jersey, kindly fill the form below.

News

Lisbon, Portugal – Hovione, the specialist integrated pharma CDMO and leader in spray drying and particle engineering, today announced its commitment to setting Science-Based Targets (SBTs) in line with the Paris Agreement. This ambitious step underscores the company’s dedication to addressing climate change and driving sustainability across its operations. By committing to SBTs, Hovione joins a growing number of businesses taking concrete actions to reduce greenhouse gas emissions. This initiative aligns with the company’s broader sustainability strategy and reinforces its commitment to scientific excellence. “At Hovione, we believe in science and in best practices. And this clearly applies to our sustainability agenda.”, said Jean-Luc Herbeaux, CEO of Hovione. We made the decision to drive our GHG emissions down using a science-based target setting process, which will help us drive sustainability across our operations by laying out a clearly defined path to reduce emissions in line with the Paris Agreement goals. We believe that by setting ambitious targets and implementing concrete actions, we can make a positive impact on the planet while driving innovation and growth.” Hovione will work closely with the Science Based Targets initiative (SBTi) to develop and validate its emission reduction targets. The company will provide regular updates on its progress towards achieving these goals. As part of its commitment to sustainability and transparency to stakeholders, the company will enhance its Ecovadis rating. Ecovadis, a leading sustainability assessment platform in the pharmaceutical industry, provides a comprehensive evaluation of a company’s environmental, social, and ethical performance, well aligned with Hovione’s sustainability ambitions.  Hovione remains dedicated to operating responsibly and contributing positively to society and the environment. The company will continue to implement sustainable practices across its operations and innovate to further improve its sustainability rating.   Learn more about Science Based-Targets  

News

Hovione Commits to Science-Based Targets for Greenhouse Gas (GHG) Emissions

Sep 09, 2024
Manufacturing Plant and R&D Center
Address

Hovione LLC
40 Lake Drive
East Windsor, NJ 08520
USA
Tel.: +1 609 918 2600
Email: contact@hovione.com
Location: 40°15'50.01" N  74°29'41.16" W

FDA logo | Hovione
VPP and C-TPAT logos | Hovione
Socma ChemStewards logos | Hovione

Other Locations

Hovione Hong Kong

Office
Address

Hovione Holding Asia Limited
Aubin House, 11th Floor
171-172 Gloucester Road
Wanchai
Hong Kong SAR
Tel.: +852 2891 1836
Fax: +852 2891 0943 

Hovione India

Office
Address

Hovione Holding Limited
C/o WeWork, 2nd floor,
Oberoi Commerz - II,  1,
Off Western Express Highway,
Oberoi Garden City, Goregaon East, Mumbai, Maharashtra 400063
India
Tel.: +919 004 261 523

Hovione Beijing

Office
Address

Hovione (Shanghai) Pharma Technology Limited Beijing Branch
Room 1003-1, 10/F, Sanyuan NEO Xinjing Building, Building 18, No. 5 Shuguang Xili, Chaoyang District, Beijing, China
Tel.: +86-18500027185
Tel.: +86-19931153253 

contact@hovione.com